



Advocacy for CLL Treatments

CLLPAG, in collaboration with Lymphoma Canada, made submissions in April 2020 supporting the funding of Venetoclax and Acalabrutinib treatments for CLL patients. Using information gathered from CLL patients in Canada and around the world, we demonstrated that these treatments were effective, had few side effects and enabled patients to regain a good quality of life. Further details on this and other advocacy initiatives are available on the [CLLPAG website](#).

Venetoclax funded in all provinces except Prince Edward Island

In 2020, all provinces except PEI have put Venetoclax and Rituximab on their formulary, which means that government or private insurance will pay for the treatment. More details on the funding conditions are available on the [Treatment Access page of the CLLPAG website](#)

Interview with Dr. Jennifer Woyach on BTK Inhibitors

Many of our members who are being treated, or are contemplating being treated, with one or more of the currently available BTK inhibitors such as Ibrutinib, Acalabrutinib, etc. will find this interview with Dr. Jennifer Woyach, hematologist at the Ohio State University Comprehensive Cancer Centre-James Cancer Hospital & Solove Research Institute of interest. [Click here for the full interview transcript.](#)

National Leukemia Conference November 16 - 20, 2020

A virtual conference to learn from experts about leukemia research innovation, and attend breakout sessions on CLL as well as AML, ALL and CML To register [click here](#)

COVID 19 - CLL patients at risk

CLL patients are at risk due to their weakened immune system, so caution is advised. Here are two Internet sites with useful information:

CLL Advocates network <https://www.clldadvocates.net/covid-19-resources/>
CLL Society : <https://cillsociety.org/covid-19/>

CLL LIVE: as a result of the COVID-19 pandemic the CLL Live 2021 has been postponed